Additionally, in HIF2α low/− clear cell renal cell carcinoma (ccRCC), FTO displays elevated expression levels, leading to increased sensitivity of ccRCC to BRD9 inhibitors (23). The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.